Form 4: Xilio Therapeutics Director Daniel J. Curran Acquires Stock Options

Daniel J. Curran, a director of Xilio Therapeutics, acquired 25,000 stock options on June 14, 2024, according to a Form 4 filing with the SEC.

Summary

• Daniel J. Curran, a director at Xilio Therapeutics, Inc. (XLO), filed a Form 4 with the SEC.
• The filing reports the acquisition of 25,000 stock options on June 14, 2024, at an exercise price of $1.02.
• These options vest on the earlier of June 14, 2025, or the next annual meeting of stockholders, contingent upon continued service to the company.
• Curran also granted a Limited Power of Attorney to Ren Russo, Christopher Frankenfield, Kevin Brennan, and Julia Walcott for Section 16 reporting obligations.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options by a director generally indicates confidence in the company's future, but it's a routine transaction.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the options is contingent upon continued service, aligning the director's interests with the company's long-term success.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding insider transactions in publicly traded companies.

Key Dates